Company: VERA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001193125-25-266881
Chunk: 16

Company: Vera Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 16
---
 narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.

•Interim, initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.

•We face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than us.

•Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.

•Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.

•Even if any product candidate we develop receives regulatory approval, it could be subject to significant post-marketing regulatory requirements and will be subject to continued regulatory oversight.

•Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

•Biosimilars to our product candidates may provide competition sooner than anticipated.

•Unfavorable geopolitical and global economic conditions, including tariffs and trade tensions, could adversely affect our business, financial condition and results of operations.

•Our success is highly dependent on our ability to attract and retain highly skilled executive officers, employees and key consultants.